In addition to the substantial clinical burden that is tied to diabetes in US, the annual economic burden that is associated with disease management jumps from $18 billion to $232 billion between the transition of pre-diabetes to full-fledged diabetes. In an effort to prevent that shift to diabetes, mitigate the development of detrimental comorbidities, and to avoid downstream consequences such as end-stage organ damage, the panelists acknowledged that it is critical to diagnose and treat patients earlier and more aggressively. Although patients will present with varying stages of disease upon initial diagnosis, there is optimism that opportunities can be created and seized to better patient outcomes, improve quality of life, and reduce the managed care burden.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
RFK Jr Claims HHS Has Not Fired Working Scientists, Canceled Lifesaving Research
May 15th 2025Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing claims of cutting down the HHS and the National Institutes of Health.
Read More
Trump Administration Walks Back Mental Health Parity in Insurance Coverage
May 13th 2025The Trump administration has decided to further debate the federal rule passed during the Biden administration that guaranteed insurance coverage for treatment of mental illness and substance abuse.
Read More